Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Construction in Progress (2016 - 2025)

Utah Medical Products has reported Construction in Progress over the past 15 years, most recently at $110000.0 for Q4 2025.

  • Quarterly results put Construction in Progress at $110000.0 for Q4 2025, up 478.95% from a year ago — trailing twelve months through Dec 2025 was $110000.0 (up 478.95% YoY), and the annual figure for FY2025 was $110000.0, up 478.95%.
  • Construction in Progress for Q4 2025 was $110000.0 at Utah Medical Products, up from $19000.0 in the prior quarter.
  • Over the last five years, Construction in Progress for UTMD hit a ceiling of $1.4 million in Q4 2023 and a floor of $19000.0 in Q4 2024.
  • Median Construction in Progress over the past 5 years was $898000.0 (2021), compared with a mean of $669200.0.
  • Biggest five-year swings in Construction in Progress: crashed 98.66% in 2024 and later skyrocketed 478.95% in 2025.
  • Utah Medical Products' Construction in Progress stood at $898000.0 in 2021, then increased by 0.89% to $906000.0 in 2022, then surged by 55.96% to $1.4 million in 2023, then crashed by 98.66% to $19000.0 in 2024, then skyrocketed by 478.95% to $110000.0 in 2025.
  • The last three reported values for Construction in Progress were $110000.0 (Q4 2025), $19000.0 (Q4 2024), and $1.4 million (Q4 2023) per Business Quant data.